Reduced‐intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) are 2 widely used reduced‐intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (allo‐SCT).

[1]  R. Gale,et al.  Should persons with acute myeloid leukemia have a transplant in first remission? , 2014, Leukemia.

[2]  B. Sandmaier,et al.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. , 2014, Blood.

[3]  Alan M. Miller,et al.  Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  A. Ganser,et al.  CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. , 2013, Blood.

[5]  M. Sorror,et al.  Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia , 2013, Expert review of hematology.

[6]  R. Hills,et al.  Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. , 2013, Blood.

[7]  E. Estey.  Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia , 2013, Leukemia.

[8]  C. Solano,et al.  The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate , 2013, Haematologica.

[9]  F. Baron,et al.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.

[10]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[11]  P. Chevallier,et al.  Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  J. Sierra,et al.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Blaise,et al.  Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison , 2009, Leukemia.

[14]  J. Sierra,et al.  Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Blaise,et al.  Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison. , 2007 .

[16]  R. Storb,et al.  Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission , 2007, Current opinion in hematology.

[17]  B. Sandmaier,et al.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  A. Nagler,et al.  Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fluda , 2007, Leukemia.

[19]  F. Baron,et al.  Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning , 2006, Leukemia.

[20]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[21]  F. Baron,et al.  Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning , 2005, Current opinion in hematology.

[22]  J. Pérez-Simón,et al.  Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning , 2003, Bone Marrow Transplantation.

[23]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[24]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[25]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. , 1997, Blood.

[26]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.